UNSPSC 51312601: Noberastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9HPD98OUWN, chemically known as 3h-imidazo(4,5-b)pyridin-2-amine, 3-((5-methyl-2-furanyl)methyl)-n-4-piperidinyl- but generally known as noberastine, which bears US NIH Compound Identifier 60531. European Medicines Agency schedules Noberastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09337MIG.

UNSPSC 51312601 Noberastine, a Commodity code, does not align with the work state and local governments are actually soliciting under this taxonomy number. Recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic pharmaceutical distribution through cooperative purchasing — none of which concerns noberastine, a pharmaceutical compound with no documented state or local procurement activity in the available records. The code shows a tagging mismatch rather than active demand for the nominal product.

Issuing bodies posting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The recent opportunities reflect pharmaceutical procurement spanning emergency response items, pharmacy benefit program innovation, and generic drug supply chains. Geographic activity centers on Florida, Texas, and Minnesota, with the cooperative purchasing vehicle extending reach across participating jurisdictions. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, with quarterly deliveries), Texas HHS's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, with awards effective July 1, 2026). Absent evidence of genuine noberastine demand, this code presents a low-priority pursuit opportunity until the tagging error is resolved or substantive activity emerges.